Abstract
Aims: To determine the allele frequencies of sulfotransferases (SULTs) 1A1 and 1A2 and their linkage disequilibrium in a Korean population and compare them with those of other ethnic groups. Methods: Genotypes of the SULT1A1*1, *2, and *3 and SULT1A2*1, *2, and *3 allelic variants were determined in 234 Korean subjects using polymerase chain reaction (PCR)–restriction fragment length polymorphism (RFLP) methods. Results: Allele frequencies for SULT1A1*1 and *2 were 0.876 [95% confidence interval (CI), 0.843–0.905] and 0.124 (95% CI, 0.096–0.157), respectively. Similarly, those for SULT1A2*1 and *2 were 0.885 (95% CI, 0.852–0.912) and 0.115 (95% CI, 0.088–0.150), respectively. However, no subject with SULT1A1*3 or SULT1A2*3 was detected. These genotype distributions are similar to those of Asian populations including the Chinese and Japanese, but quite different from other ethnic groups such as African-Americans and Caucasians. The expected allelic frequencies of SULT1A1 and SULT1A2 at Hardy–Weinberg equilibrium are quite similar to the observed distributions in the population. SULT1A1*2 and SULT1A2*2, the most common variant alleles of these two genes, are strongly and positively linked in the Korean population (D′=0.8919, χ2 =343.24, P=0.0034). Conclusions: SULT1A1*2 and SULT1A2*2 are the major allelic variants in the Korean population, whereas the SULT1A1*3 and SULT1A2*3 alleles were not found. SULT1A1*2 and SULT1A2*2 are strongly linked.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Cytosolic sulfotransferases (SULTs) play an important role in the phase II metabolism of several xenobiotics. Sulfation can result in either inactivation or the metabolic activation of sulfate acceptor substrates [1, 2]. Functional polymorphisms of the SULT1As may influence individual susceptibility to adverse drug reactions involving drug substrates and to chemical carcinogenesis [3–6]. The human SULT1A subfamily contains several members, which share over 92% identity at the amino acid level [7–9]. SULT1A1 is an important enzyme in xenobiotic metabolism because it has broad substrate specificity with a high affinity for many compounds and it is expressed widely in the body, particularly in the liver, brain, jejunum, and platelets [10–12]. Importantly, SULT1A1 is subject to a common functional polymorphism [13, 14], with the variant allele (SULT1A1*2, allele frequency 32% in Caucasians) encoding an allozyme with a single amino acid change (Arg213His) that is uniformly associated with low SULT activity and low thermal stability [15]. Another single amino acid change, Met223Val, in SULT1A1*3 is also commonly detected in several ethnic groups, especially African-Americans [14, 15]. Like SULT1A1, SULT1A2 is highly polymorphic, and several polymorphisms have been detected in humans [9, 14, 16]. SULT1A2*2 differs from SULT1A2*1 at two amino acid residues (Ile7Thr and Asn235Thr) [15]. The change at codon 235 appears to be particularly important functionally. Threonine in that position drastically reduces the affinity for the substrate 4-nitrophenol [15–17].
It has been reported that the gene SULT1A2 is usually in linkage disequilibrium with SULT1A1 and that the high-activity alloenzymes (SULT1A1*1 and SULT1A2*1) are associated in several ethnic groups [18, 19]. Moreover, the genes for the low-affinity alloenzymes (SULT1A1*2 and SULT1A2*2) are also associated.
In this study, we determined the allele frequencies of SULT1A1 and SULT1A2 using polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) assays designed to detect common variant alleles of SULT1A1 and SULT1A2. We then assessed the linkage disequilibrium between these two genes in a Korean population. Finally, we compared the results with those for other ethnic populations.
Materials and methods
Study population
After written informed consent was obtained from participants, blood samples were collected from 234 healthy Korean subjects. Genomic DNA was isolated from peripheral blood using the QIAamp Blood Kit (Qiagen, Chatsworth, CA, USA). All the samples were collected under conditions that had been reviewed and approved by the Institutional Review Board of Gil Medical Center, Gachon Medical School, Incheon, Korea.
Identification of SULT1A1 and SULT1A2 polymorphisms
The presence of alleles of both SULT1A1*2 or 1A1*3 and SULT1A2*2 or 1A2*3 was determined by PCR-RFLP analysis as previously described, with a slight modification [20]. HhaI, Hsp92II, BstEII, and BstU1 were used as restriction enzymes for SULT1A1*2 or SULT1A1*3 and SULT1A2*2 or SULT1A2*3, respectively.
Statistical analysis
Statistical analysis was performed with SPSS version 12.0 (SPSS, IL, USA), using a chi-square (χ2) test. Linkage analysis was performed with the Estimating Haplotype Frequency Test using the EH program (http://linkage.rockefeller.edu/soft/) described by Terwilliger and Ott [21] with the population-based sampling method. D′ values, a standard measure of linkage disequilibrium, were calculated as D/D max , where D is the coefficient of linkage disequilibrium, indicating the amount of disequilibrium (−0.25< D<0.25) [22]. Because D depends on allele frequencies, the standardized value D′ is preferred [23]. D′ values can vary from +1 when alleles at the two loci studied are maximally positively associated (that is, always occurring together in the same haplotype) to −1 when the alleles are maximally negatively associated (that is, never occurring together in the same haplotype).
Results
The SULT1A1 and SULT1A2 genotypes were determined in 234 healthy Korean subjects (195 males, 39 females). The observed allelic frequencies of SULT1A1*1 and SULT1A1*2 were 0.876 and 0.124, respectively. However, we found no subject carrying the SULT1A1*3 allele in this population. The allelic frequencies of SULT1A2*1 and SULT1A2*2 were 0.885 and 0.115, respectively, but no subject carried the SULT1A2*3 allele (Table 1). The expected allelic frequencies of SULT1A1 and SULT1A2 estimated at Hardy–Weinberg equilibrium were quite similar to the observed distributions in the population (χ2 =4.475, P=0.107 for SULT1A1, χ2 =3.378, P=0.185 for SULT1A2). There were no significant gender differences in allele frequencies for SULT1A1 or SULT1A2 (χ2 =0.0269, P=0.870 for SULT1A1, χ2 =0.0031, P=0.956 for SULT1A2).
We estimated the allele frequencies of SULT1A1 and SULT1A2 to determine whether the two alleles mapped together or independently. The results showed that the observed subject numbers were quite similar to the expected numbers, assuming that the two genes are associated (Table 2). The statistical hypothesis that these alleles are independently distributed was rejected (χ2 =159.2, P<0.001), indicating that the two genes are strongly linked. Furthermore, the calculated value of D′, the coefficient of linkage disequilibrium, showed a strong positive linkage between SULT1A1*2 and SULT1A2*2 (D′=0.8919, χ2 =343.24, P=0.0034) in this population.
Discussion
In this study we compared the frequencies of all six common SULT1A1 and SULT1A2 alleles that occur in the Korean population with the frequencies of those same alleles in other ethnic groups, and we observed striking ethnic differences compared with African-American and Caucasian populations [19]. However, the allele frequencies for SULT1A1 and SULT1A2 were similar to those of Chinese and Japanese populations [19]. We could not find any allele of SULT1A1*3 or SULT1A2*3 in this population. Similarly, other Asian ethnic groups, including the Chinese and Japanese, had very low frequencies of these alleles, whereas African-Americans had higher frequencies (0.23 for SULT1A1 and 0.11 for SULT1A2) [19]. Even though we found no subject with the allele of SULT1A1*3 or SULT1A2*3 in this population, the small sample size might have limited the detection of these alleles. Therefore, the study should be conducted with larger populations.
In this study, the allele frequencies of SULT1A2*1 and *2 were very similar to those of the SULT1A1*1 and *2 alleles. Because the expected allele frequencies of SULT1A1 and SULT1A2 estimated at Hardy–Weinberg equilibrium was quite similar to the observed distribution, we assessed whether SULT1A1 and SULT1A2 are associated by estimating their haplotype frequencies [24]. The frequencies of the alleles SULT1A1*1 (0.876) and 1A2*1 (0.885) and of the haplotype SULT1A1*1/1A2*1 (0.752) were comparable, suggesting that nearly all SULT1A1*1 alleles (97.1%) are associated with SULT1A2*1 and, conversely, that most SULT1A1*2 alleles (84.5%) are associated with SULT1A2*2. On the other hand, the frequencies of the other two haplotypes, SULT1A1*1/1A2*2 and SULT1A1*2/1A2*1, were very low in the Korean population (3.9 and 2.1%, respectively). The association between SULT1A1 and SULT1A2 is consistent with previous data reported [19]. Furthermore, the calculated D′ value is close to +1.0 (D′=0.8919), indicating that the two genes are strongly and positively linked. This value is similar to that for the Chinese population but higher than those for the Caucasian and African-American populations [19]. The SULT1A genes, including SULT1A1 and SULT1A2, are located in the chromosomal region 16p11.2–12.1 [25]. The encoded proteins have the same number of amino acid residues (295 amino acids) and 93–96% identity in the amino acid sequences, but they differ substantially in their substrate specificity and regulation [26]. In addition, a previous study in which the SULT1A1 gene was cloned suggested that SULT1A1 and SULT1A2 are approximately 45 kb apart and oriented head-to-tail [25]. These findings may explain the strong positive linkage disequilibrium of the two genes. However, until now, there has been no clear demonstration of this association at a mechanistic level.
SULT1A1 and SULT1A2 are the focus of intense research in the fields of cancer, drug metabolism, and pharmacogenetics because genetic variation may predispose carriers to lung cancers [27], protect against colorectal cancers [4], and affect the age of onset of breast cancer [5]. In the case of drug metabolism, SULT1A1 and SULT1A2 are involved in the sulfation of various drugs and chemicals [28, 29]. Rossi et al. [30] have shown that the sulfation rate for 4-nitrophenol, a substrate of SULT1A, by isoenzyme SULT1A1*2/*2 was significant lower than that by that of SULT1A1*1/*1 or *1/*2. Therefore, it would be important to determine the difference in biochemical properties based on the genetic polymorphisms of SULT1A1 and SULT1A2 in humans. As mentioned above, the allele frequencies in this population are very close to those observed in other Asian populations but are fairly different from those observed in Caucasians and African-Americans. Therefore, sulfation of certain substance may be clinically significantly different between these populations and thus affect the occurrence of sulfation-related toxicities and diseases. However, little is known of the roles of the genetic polymorphisms of these two genes, and future research should be directed to that end.
In summary, we have demonstrated that SULT1A1*2 and SULT1A2*2 are major allelic variants but that SULT1A1*3 and SULT1A2*3 are rare in the Korean population. Furthermore, SULT1A1 and SULT1A2 are strongly and positively linked in this population.
Abbreviations
- SULT :
-
Sulfotranseferase
- D′:
-
Constant for linkage disequilibrium
References
Otterness DM, Weinshilboum R (1994) Human dehydroepiandrosterone sulfotransferase: molecular cloning of cDNA and genomic DNA. Chem Biol Interact 92:145–159
Falany CN (1997) Enzymology of human cytosolic sulfotransferases. FASEB J 11:206–216
Nebert DW (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60:265–271
Bamber DE, Fryer AA, Strange RC, Elder JB, Deakin M, Rajagopal R, Fawole A, Gilissen RAHJ, Campbell FC, Coughtrie MWH (2001) Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced risk of colorectal cancer. Pharmacogenetics 11:679–685
Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K (2000) Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60:6859–6863
Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB (2002) Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94:1635–1640
Wilborn TW, Comer KA, Dooley TP, Reardon IM, Heinrikson RL, Falany CN (1993) Sequence analysis and expression of the cDNA for the phenol-sulfating form of human liver phenol sulfotransferase. Mol Pharmacol 43:70–77
Zhu X, Veronese ME, Sansom LN, McManus ME (1993) Molecular characterisation of a human aryl sulfotransferase cDNA. Biochem Biophys Res Commun 192:671–676
Ozawa S, Nagata K, Shimada M, Ueda M, Tsuzuki T, Yamazoe Y, Kato R (1995) Primary structures and properties of two related forms of aryl sulfotransferases in human liver. Pharmacogenetics 5:S135–S140
Hart RF, Renskers KJ, Nelson EB, Roth JA (1979) Localization and characterization of phenol sulfotransferase in human platelets. Life Sci 24:125–130
Rein G, Glover V, Sandler M (1982) Multiple forms of phenolsulphotransferase in human tissues: selective inhibition by dichloronitrophenol. Biochem Pharmacol 31:1893–1897
Young WF Jr, Okazaki H, Laws ER Jr, Weinshilboum RM (1984) Human brain phenol sulfotransferase: biochemical properties and regional localization. J Neurochem 43:706–715
Coughtrie MWH, Gilissen RAHJ, Shek B, Strange RC, Fryer AA, Jones PW, Bamber DE (1999) Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 337:45–49
Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298–304
Raftogianis RB, Wood TC, Weinshilboum RM (1999) Human phenol sulfotransferases SULT1A2 and SULT1A1. Genetic polymorphisms, allozyme properties, and human liver genotype–phenotype correlations. Biochem Pharmacol 58:605–616
Zhu X, Veronese ME, Iocco P, McManus ME (1996) cDNA cloning and expression of a new form of human aryl sulfotransferase. Int J Biochem Cell Biol 28:565–571
Meinl W, Meerman JH, Glatt H (2002) Differential activation of promutagens by alloenzymes of human sulfotransferase 1A2 expressed in Salmonella typhimurium. Pharmacogenetics 12:677–689
Engelke CEH, Meinl W, Boeing H, Glatt H (2000) Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. Pharmacogenetics 10:163–169
Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, Weinshilboum RM (2001) Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11:57–68
Peng CT, Chen JC, Yeh KT, Wang YF, Hou MF, Lee TP, Shih MC, Chang JY, Chang JG (2003) The relationship among the polymorphisms of SULT1A1, 1A2 and different types of cancers in Taiwanese. Int J Mol Med 11:85–89
Terwilliger JD, Ott J (1993) A novel polylocus method for linkage analysis using the lod-score or affected sib-pair method. Genet Epidemiol 10:477–482
Falconer DS, Mackay TFC (1989) Introduction to quantitative genetics, 4th edn. Longman Group, Harlow
Hartl DL, Clark AG (1989) Principles of population genetics, 2nd edn. Sinauer Associates, Sunderland, MA
Nagata K, Yamazoe Y(2000) Pharmacogenetics of sulfotransferase. Annu Rev Pharmacol Toxicol 40:159–176
Raftogianis RB, Her C, Weinshilboum RM (1996) Human phenol sulfotransferase pharmacogenetics: STP1 gene cloning and structural characterization. Pharmacogenetics 6:473–487
Honma W, Kamiyama Y, Yoshinari K, Sasano H, Shimada M, Nagata K, Yamazoe Y (2001) Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab Dispos 29:274–281
Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N, Wu X (2002) Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 35:137–142
Levy RH, Thummel KE, Trager WF, Hanstein PD, Eichelbaum M (2000) Sulfotransferase and methyltransferase. In: Metabolic drug interactions, 1st edn. Lippincott Williams & Wilkins, Philadelphia, pp 191–204
Kauffman FC (2004) Sulfonation in pharmacology and toxicology. Drug Metab Rev 36:823–843
Rossi AM, Maggini V, Fredianelli E, Di Bello D, Pietrabissa A, Mosca F, Barale R, Pacifici GM (2004) Phenotype–genotype relationships of SULT1A1 in human liver and variations in the IC50 of the SULT1A1 inhibitor quercetin. Int J Clin Pharmacol Ther 42:561–567
Acknowledgments
This work was supported by Korea Research Foundation Grant R0-2004-000-11952-0.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, KA., Lee, SY., Park, PW. et al. Genetic polymorphisms and linkage disequilibrium of sulfotransferase SULT1A1 and SULT1A2 in a Korean population: comparison of other ethnic groups. Eur J Clin Pharmacol 61, 743–747 (2005). https://doi.org/10.1007/s00228-005-0989-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0989-3